Open access
Open access
Powered by Google Translator Translator

Chest Medicine (all articles)

Systematic Review: Risks and Impact of ACE Inhibitors or ARBs on SARS-CoV-2 Infection in Adults

18 May, 2020 | 01:47h | UTC

Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review – Annals of Internal Medicine

Editorial: COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy – Annals of Internal Medicine

 


Study: Use of Renin–angiotensin–aldosterone System Inhibitors Does Not Increase the Risk of COVID-19 Requiring Admission to Hospital

18 May, 2020 | 01:45h | UTC

Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study – The Lancet

Commentary: Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19 – The Lancet

 


[Preprint] Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients

15 May, 2020 | 03:50h | UTC

Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients – medRxiv

Commentary: Convalescent plasma is safe to treat COVID-19: nationwide study – NBC News

 


Systematic Review: Plasma from People who Have Recovered from COVID-19 to Treat Individuals with COVID-19

15 May, 2020 | 03:48h | UTC

Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a rapid review – Cochrane Library

Summary: Plasma from people who have recovered from COVID-19 to treat individuals with COVID-19 – Cochrane Library

 


Study: Airborne Lifetime of Small Speech Droplets and their Potential Importance in SARS-CoV-2 Transmission

15 May, 2020 | 03:43h | UTC

The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission – Proceedings of the National Academy of Sciences

Commentaries: Expert reaction to study looking at speech-generated droplets and COVID-19 transmission – Science Media Centre AND Loud Talking Can Spread More than 1,000 Coronavirus Particles in the Air for 14 Minutes: Study – The Science Times AND Simply talking in confined spaces may be enough to spread the coronavirus, researchers say – USA Today AND Loud talking could leave coronavirus in the air for up to 14 minutes – MIT Technology Review

 


ACP Systematic Review: Chloroquine or Hydroxychloroquine Alone or in Combination with Azithromycin for the Prophylaxis or Treatment of COVID-19

15 May, 2020 | 03:32h | UTC

Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? – Annals of Internal Medicine

 


Study Commentary: Before/after Study of Short-Course Steroid in COVID-19

14 May, 2020 | 10:09h | UTC

Before/after study of short-course steroid in COVID-19 – PulmCrit

Original Study (Preprint): Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 – medRxiv

 


New Study Does Not Support the Idea that BCG Vaccination Protects Against COVID-19

14 May, 2020 | 10:12h | UTC

SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults – JAMA

Related: BCG Against Coronavirus: Less Hype And More Evidence, Please – Forbes AND Does BCG vaccination protect against acute respiratory infections and COVID-19? A rapid review of current evidence – CEBM University of Oxford AND Bacille Calmette-Guérin (BCG) vaccination and COVID-19 – World Health Organization

 


Review: Pulmonary Complications Associated with Veno-arterial ECMO

14 May, 2020 | 02:22h | UTC

Pulmonary complications associated with veno-arterial extra-corporeal membrane oxygenation: a comprehensive review – Critical Care

 


ERS Guideline: Withdrawal of Inhaled Corticosteroids in COPD

14 May, 2020 | 02:17h | UTC

Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A European Respiratory Society Guideline – European Respiratory Journal

 


Research Round-up: COPD

14 May, 2020 | 02:20h | UTC

Research round-up: COPD – Nature

Related: Should physicians still be prescribing steroid inhalers as a first-line treatment for COPD? – Nature AND Redefining the diagnostic criteria for COPD – Nature

See other articles from the series:  Nature Outlook on COPD

 


Cohort Study: Pulmonary Rehabilitation Linked to Improved Survival After Hospitalization for COPD

14 May, 2020 | 02:14h | UTC

Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries – JAMA (free for a limited period)

Editorial: Pulmonary Rehabilitation and Improved Survival for Patients With COPD (free for a limited period)

 


Interpreting a Covid-19 Test Result

13 May, 2020 | 02:18h | UTC

Practice Pointer: Interpreting a covid-19 test result – The BMJ

Related: Interpreting Diagnostic Tests for SARS-CoV-2 – JAMA

 


New Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

13 May, 2020 | 02:14h | UTC

Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19 – JAMA Internal Medicine

See also: Calculation Tool For Predicting Critical-ill COVID-19 At Admission

Related Preprint Study (just published): Development and validation of the COVID-19 severity index (CSI): a prognostic tool for early respiratory decompensation – medRxiv AND Calculation Tool: https://covidseverityindex.org/

 


Study Commentary – Virus Wars: Return of Lopinavir/Ritonavir (Along with Ribavirin and Interferon)

13 May, 2020 | 02:12h | UTC

Virus Wars: Return of Lopinavir/Ritonavir (along with ribavirin and interferon) – PulmCrit

Original Article: Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial (study and commentaries)

 


Hydroxychloroquine in Patients with COVID-19: A Systematic Review and Meta-analysis

13 May, 2020 | 01:53h | UTC

“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.” – Diabetes & Metabolic Syndrome: Clinical Research & Reviews

“While initial studies with hydroxychloroquine showed some ray of hope, recent studies that have emerged found either no benefit or a possible harm in COVID-19.”

 


Remdesivir in COVID-19: A Critical Review of Pharmacology, Pre-clinical and Clinical Studies

13 May, 2020 | 01:50h | UTC

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies – Diabetes & Metabolic Syndrome: Clinical Research & Reviews

“While the first double-blind, randomized-controlled trial (DBRCT) found no significant benefit with remdesivir compared to placebo, preliminary reports from another DBRCT showed a significant faster recovery, without any difference in mortality.”

 


The FDA has Authorized the use of Remdesivir: But There’s no Good Evidence it Reduces Mortality in Covid-19

13 May, 2020 | 01:49h | UTC

The FDA has authorised remdesivir for use in COVID-19 patients: but there’s no good evidence it reduces mortality – CEBM Oxford

 


Observational Study: Hydroxychloroquine, Azithromycin, or Both Not Associated with Lower In-hospital Mortality

12 May, 2020 | 03:39h | UTC

Association of Treatment with Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State – JAMA

Related: Large Observational Study Finds Hydroxychloroquine Provides no Benefit in Hospitalized Patients with Covid-19

 


Coagulation Abnormalities and Thrombosis in Patients with COVID-19

12 May, 2020 | 03:16h | UTC

Coagulation abnormalities and thrombosis in patients with COVID-19 – The Lancet

 

Related Commentary on Twitter

 


Perspective: Which COVID-19 Antivirals Actually Work?

12 May, 2020 | 03:18h | UTC

Perspective: Which COVID-19 Antivirals Actually Work? – Forbes

Related: Hong Kong Doctors See Progress In Treatment Of COVID-19 – Forbes

 


Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation

12 May, 2020 | 03:08h | UTC

Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR) – Mayo Clinic Proceedings

Related: Medical Reversals in Family Practice: A Review – Current Therapeutic Research AND Meta-Research: A Comprehensive Review of Randomized Trials Leading to “Medical Reversals” in Three Medical Journals

 


Triple Therapy Antiviral Combination Seems Promising for COVID-19 in Open-label, Randomized, Phase 2 Trial

11 May, 2020 | 00:42h | UTC

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial – The Lancet

Commentaries: Interferon beta-1b for COVID-19 – The Lancet AND New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial – The Lancet AND A Drug Cocktail Hastens Recovery in Some Coronavirus Patients – The New York Times AND Triple drug therapy helps coronavirus patients recover more quickly, study finds – CNN AND Triple antiviral drug shows early promise in COVID-19 trial – Reuters AND Expert reaction to a study about a phase 2 trial of a triple antiviral drug combination treatment for COVID-19 – Science Media Centre

 


Preliminary Study Evaluates Interleukin-1 Blockade for Patients with Severe Covid-19

11 May, 2020 | 00:34h | UTC

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study – The Lancet Rheumatology

Commentaries: Expert reaction to study looking at use of arthritis drug anakinra in hospitalised patients with severe COVID-19 – Science Media Centre AND Small study of patients with severe COVID-19 treated with the arthritis drug anakinra finds clinical improvements – The Lancet

 


The Emerging Long-term Complications of Covid-19, Explained

11 May, 2020 | 00:27h | UTC

The emerging long-term complications of Covid-19, explained – Vox

Related: Coronavirus: Sickest patients face long recovery – BBC AND Surviving Covid-19 May Not Feel Like Recovery for Some – New England Journal of Medicine

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.